AXL and neoplasm: Accompanying this were significant changes in regulators of inflammation that were consistent with a shift from AXL to MERTK signaling, which have been distinguished in carefully controlled studies [43] that refine our understanding of TAM receptor signaling in tumor immune surveillance [51, 52].